Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2013.126 | Literacy Training to Improve Neurocognitive Functions in Low-Income Mild Cognitive Impairment Patients | Prof. Wong Patrick Chun Man |
| 2013.124 | Behavioral and Neurologic Factors in Speech Learning | Prof. WONG Patrick Chun Man |
| 2012.469 | Musical and Lexical Tone Deafness | Prof. WONG Patrick Chun Man |
| 2016.006 | Neurogenetics of English language learning in primary school children in Hong Kong |
Prof. WONG Patrick Chun Man 黃俊文 |
| 2014.412 | Neural responses to pitch in Cantonese-speaking children with autism spectrum disorders | Prof. WONG Patrick Chun Man |
| 2016.326 | Improving cognitive functions in mild cognitive impairment via mobile-app foreign language learning |
Prof. WONG Patrick Chun Man 黃俊文 |
| 2017.102 | The Neurophysiological Basis of Early Speech Perception and Language Learning |
Prof. WONG Patrick Chun Man 黃俊文 |
| 2015.410 | The Neural Basis of Language and Cognitive Development |
Prof. WONG Patrick Chun Man 黃俊文 |
| 2021.523 | A Predict-to-Prescribe Approach to Social Communication Treatment in Chinese Preschool Children with Autism Spectrum Disorder |
Prof. WONG Patrick Chun Man 黃俊文 |
| 2008.464 | A Descriptive Questionnaire Survey: The Factors Influence the Implementation of Auscultation by Nurses | Ms Wong Po Wa |
| 2021.273 | Optical Coherence Tomography and Optical Coherence Tomography Angiography features in Cytomegalovirus Retinitis | Dr. WONG Po Yin |
| 2020.081 | Characterising Right Ventricular Fibrosis and Abnormal Strain in Systemic Lupus Erythematosus with Pulmonary Hypertension – a Magnetic Resonance Imaging and Echocardiographic Correlation Study |
Dr. WONG Priscilla Ching Han 王靜嫻 |
| 2018.262 | Quantitative assessment of the spondyloarthritis severity by using Diffusion Weighted Imaging in 3T magnetic resonance imaging. |
Dr. WONG Priscilla Ching Han 王靜嫻 |
| 2022.083 | Radiogenomics approach to determine the prevalence of Genetically Triggered Thoracic Aortic Aneurysm and Dissection and guide genetic counselling in Hong Kong |
Dr. WONG Randolph Hung Leung 黃鴻亮 |
| 2023.286 | Frailty trajectories and factors associated with frailty change among patients undergoing cardiac surgeries or transcatheter procedures: a mixed-methods prospective longitudinal study | Prof. WONG Randolph Hung Leung |
| 2024.109 | Determinants of event-free survival and late reintervention after the Bentall procedure: A single-centre retrospective study |
Prof. WONG Randolph Hung Leung 黃鴻亮 |
| 2024.110 | Determinants of early and late survival after surgery for cardiac tumours |
Prof. WONG Randolph Hung Leung 黃鴻亮 |
| 2023.075 | Randomized trial on Acutely Dissected Aorta Repair with Hemiarch replacement with or without stent implantation (RADAR trial) |
Prof WONG Randolph Hung Leung 黃鴻亮 |
| 2024.067 | AI-powered Multimodality approach to screen and diagnose Thoracic Aortic Aneurysm and Dissection (TAAD) |
Prof. WONG Randolph Hung Leung 黃鴻亮 |
| 2021.236 | NEOS-APAC – Asian Pacific post-market clinical follow-up study in patients with acute or chronic aortic dissection or aortic aneurysm treated with E-vita OPEN NEO |
Dr. WONG Randolph Hung Leung 黃 鴻 亮 |
| 2015.669 | Pocket-size mobile echocardiographic device screening for thoracic aortic aneurysm in Chinese hypertensive patients |
Dr. WONG Randolph Hung Leung 黃鴻亮 |
| 2022.134 | Impact of cholesterol level on long-term angiographic outcome of CABG patients | Dr. WONG Randolph Hung Leung |
| 2024.394 | Mycophenolate mofetil in Chinese patients with immune thrombocytopenia | Dr. WONG Raymond |
| 2008.042 | A Phase 3 Randomized, Open-label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Phildadelphia Chromosome Positive Chronic Myelogenous Leukemia | Dr. WONG Raymond |
| 2013.269 | A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFUSE LARGE B-CELL LYMPHOMA OR CD20+ FOLLICULAR NON-HODGKIN’S LYMPHOMA GRADES 1, 2 OR 3A | Dr. WONG Raymond Siu Ming |
| 2011.479 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B | Dr. WONG Raymond Siu Ming |
| 2012.419 | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Dr. WONG Raymond Siu Ming |
| 2011.278 | A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy | Dr. WONG Raymond Siu Ming |
| 2012.257 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma | Dr. WONG Raymond Siu Ming |
| 2009.309 | An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed / Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation | Dr. WONG Raymond Siu Ming |
| 2014.111 | A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. | Dr. WONG Raymond Siu Ming |
| 2009.308 | A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy | Dr. WONG Raymond Siu Ming |
| 2014.112 | Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag. | Dr. WONG Raymond Siu Ming |
| 2009.494 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman Disease | Dr. WONG Raymond Siu Ming |
| 2011.395 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). | Dr. WONG Raymond Siu Ming |
| 2009.457 | An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 +chlorambucil (GClb), rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities | Dr. WONG Raymond Siu Ming |
| 2011.538 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A | Dr. WONG Raymond Siu Ming |
| 2012.292 | A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma | Dr. WONG Raymond Siu Ming |
| 2009.489 | A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and tranfusional iron overload (TELESTO) | Dr. WONG Raymond Siu Ming |
| 2006.286 | EXTEND (Eltrombopag eXTENded Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, with Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in An Eltrombopag Study | Prof. WONG Raymond Siu Ming |
| 2012.305 | A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment. | Dr. WONG Raymond Siu Ming |
| 2008.068 | A Phase 1 / 2 Study of CMC-544 Administered in Combination with Rituximab in Subjects with Follicular or Diffuse Large B-Cell Non-Hodgkin’s Lymphoma | Prof. WONG Raymond Siu Ming |
| 2010.030 | A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma | Dr. WONG Raymond Siu Ming |
| 2013.430 | AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | Dr. WONG Raymond Siu Ming |
| 2022.655 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2021.521 | A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Subjects with Inadequate Response to C5 Inhibitor Therapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.072 | A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.152 | A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) CURRENTLY TREATED WITH COMPLEMENT INHIBITORS |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.267 | A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.462 | A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria |
Dr. WONG Raymond Siu Ming 王紹明 |
Page 226 of 254.